miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis.
View/ Open
Date
2019-02-01Author
Fassan, M
Cui, R
Gasparini, P
Mescoli, C
Guzzardo, V
Vicentini, C
Munari, G
Loupakis, F
Lonardi, S
Braconi, C
Scarpa, M
D'Angelo, E
Pucciarelli, S
Angriman, I
Agostini, M
D'Incá, R
Farinati, F
Gafà, R
Lanza, G
Frankel, WL
Croce, CM
Valeri, N
Rugge, M
Type
Journal Article
Metadata
Show full item recordAbstract
miR-224 has recently emerged as a driver oncomiR in sporadic colorectal carcinogenesis, but its pathogenetic role is still controversial. A large phenotypical and molecularly characterized series of preinvasive and invasive colorectal lesions was investigated for miR-224 expression by qRT-PCR and in situ hybridization. The caspase-3 and caspase-7 status was also assessed and correlated to miR-224 dysregulation. miR-224 was significantly upregulated during the adenoma-carcinoma sequence and in the context of inflammatory bowel disease dysplastic lesions, whereas its expression was significantly downregulated among BRAF-mutated tumors and in the presence of a DNA mismatch repair deficiency. miR-224 targets caspase-3 and caspase-7 in colorectal cancer, and this inverse relation was already evident from the earliest phases of transformation in intestinal mucosa. The miR-224/caspases axis may represent an interesting field of study for innovative biomarkers/therapeutics for BRAF-mutated/DNA mismatch repair-deficient tumors.
Collections
Research team
Signal Transduction & Molecular Pharmacology
Gastrointestinal Cancer Biology and Genomics
Language
eng
Date accepted
2018-10-31
License start date
2019-02
Citation
Translational oncology, 2019, 12 (2), pp. 282 - 291
Publisher
ELSEVIER SCIENCE INC